Quick answers
- What is Metoprolol tartrate and hydrochlorothiazide used for?
- The FDA-approved label (Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc., September 15, 2026) says: “Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Metoprolol tartrate and hydrochlorothiazide?
- The “Adverse Reactions” section of the FDA label (Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc., September 15, 2026) begins: “The following adverse reactions are described in more detail elsewhere in the label; • Worsening angina or myocardial infarction [see Warnings and Precautions (5)] • Worsening heart failure [see Warnings and Precautions (5)] • Worsening AV block [see Contraindications (4)] To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.2 Post-Marketing Experience The following adverse reactions have been reported in postmarketing experience: adverse reactions have been identified during post approval use of metoprolol tartrate and hydrochlorothiazide tablets.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Metoprolol tartrate and hydrochlorothiazide?
- The “Drug Interactions” section of the FDA label (Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc., September 15, 2026) begins: “• Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (7.1) • CYP2D6 inhibitors: Increased metoprolol concentration. (12.3) • Digitalis glycosides, clonidine, diltiazem and verapamil: Bradycardia. (5.4, 7.1) • Clonidine: Rebound hypertension following clonidine withdrawal. (7.1) • Antidiabetic drugs: Dosage adjustment may be required. (7.2) • Cholestyramine and colestipol: Reduced absorption of thiazides. (7.2) • Lithium: Risk of lithium toxicity.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Metoprolol tartrate and hydrochlorothiazide have a boxed warning?
- No. None of the 5 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Metoprolol tartrate and hydrochlorothiazide?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Metoprolol tartrate and hydrochlorothiazide been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started March 15, 2021 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Metoprolol tartrate and hydrochlorothiazide?
- 5 companies list prescription products of Metoprolol tartrate and hydrochlorothiazide in the FDA NDC Directory, including Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc. and Mylan Pharmaceuticals Inc.
What Metoprolol tartrate and hydrochlorothiazide is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. …
— FDA label: Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc., effective September 15, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (tablet, oral), Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc.; it covers 3 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 5 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 5 FDA labels for this medicine have a boxed warning.
Metoprolol tartrate and hydrochlorothiazide side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following adverse reactions are described in more detail elsewhere in the label;
- Worsening angina or myocardial infarction [see Warnings and Precautions (5)]
- Worsening heart failure [see Warnings and Precautions (5)]
- Worsening AV block [see Contraindications (4)] To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.2 Post-Marketing Experience The following adverse reactions have been reported in postmarketing experience: adverse reactions have been identified during post approval use of metoprolol tartrate and hydrochlorothiazide tablets.
Read more of this section
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Metoprolol Confusional state, an increase in blood triglycerides and a decrease in High Density Lipoprotein (HDL). Very rare reports of hepatitis, jaundice and non-specific hepatic dysfunction. Isolated cases of transaminase, alkaline phosphatase, and lactic dehydrogenase elevations have also been reported. Hydrochlorothiazide Digestive: Pancreatitis, jaundice (intrahepatic cholestatic), sialadenitis, vomiting, diarrhea, cramping, nausea, gastric irritation, constipation, anorexia. Cardiovascular: Orthostatic hypotension (may be potentiated by alcohol, barbiturates, or narcotics). Neurologic: Vertigo, dizziness, transient blurred vision, headache, paresthesia, xanthopsia, weakness, restlessness. Musculoskeletal: Muscle spasm. Hematologic: Aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia. Metabolic: Hyperglycemia, glycosuria, hyperuricemia. Hypersensitive Reactions: Necrotizing angiitis, Stevens-Johnson syndrome, respiratory distress including pneumonitis and pulmonary edema, purpura, urticaria, rash, photosensitivity. Other Beta-Adrenergic Agent Reactions A variety of adverse reactions have been reported with other beta-adrenergic blocking agents and should be considered potential adverse reactions to metoprolol tartrate. Central Nervous System: Reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place, emotional lability, clouded sensorium, and decreased performance on neuropsychometrics. Hematologic: Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura. Hypersensitive Reactions: Laryngospasm and respiratory distress.
— FDA label: Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc., effective September 15, 2026. Read the full label on DailyMed →
Metoprolol tartrate and hydrochlorothiazide drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
- Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (7.1)
- CYP2D6 inhibitors: Increased metoprolol concentration. (12.3)
- Digitalis glycosides, clonidine, diltiazem and verapamil: Bradycardia. (5.4, 7.1)
- Clonidine: Rebound hypertension following clonidine withdrawal. (7.1)
- Antidiabetic drugs: Dosage adjustment may be required. (7.2)
- Cholestyramine and colestipol: Reduced absorption of thiazides. (7.2)
- Lithium: Risk of lithium toxicity.
Read more of this section
(7.2)
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (7.2) 7.1 Drug Interactions with Metoprolol Catecholamine Depleting Drugs The concomitant use of catecholamine-depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) with beta adrenergic blockers may have an additive affect and increase the risk of hypotension or bradycardia. CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to increase metoprolol concentration. Increases in plasma concentration decrease the cardioselectivity of metoprolol [see Clinical Pharmacology (12.3)]. Monitor patients closely when the combination cannot be avoided. Digitalis, Clonidine, and Calcium Channel Blockers Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. Concomitant use with beta blockers can increase the risk of bradycardia. If clonidine and a beta-blocker, such as metoprolol are coadministered, withdraw the beta-blocker several days before the gradual withdrawal of clonidine because beta-blockers may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, delay the introduction of beta-blockers for several days after clonidine administration has stopped. 7.2 Drug Interactions with Hydrochlorothiazide Antidiabetic Drugs (oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required. Ion Exchange Resins Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. Stagger the dosage of hydrochlorothiazide and ion exchange resins (e.g., cholestyramine and colestipol resins) such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins to minimize the interaction. Lithium Diuretics reduce the renal clearance of lithium and increase the risk of lithium toxicity. Monitor serum lithium concentrations during concurrent use. Non-Steroidal Anti-Inflammatory Drugs NSAIDs can reduce the diuretic, natriuretic, and antihypertensive effects of thiazide diuretics.
— FDA label: Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc., effective September 15, 2026. Read the full label on DailyMed →
Metoprolol tartrate and hydrochlorothiazide dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
- Usual dose range: Hydrochlorothiazide 12.5 to 25 mg and metoprolol tartrate 100 mg dosed once daily. (2.1) 2.1 Recommended Dosage Titrate doses of individual components before switching to metoprolol tartrate and hydrochlorothiazide tablets. Administer metoprolol tartrate and hydrochlorothiazide tablets with or immediately following meals. Hydrochlorothiazide is usually given at a dosage of 12.5 mg to 50 mg per day.
Read more of this section
The usual initial dosage of metoprolol is 100 mg daily in single or divided doses. Dosage may be increased gradually until optimum blood pressure control is achieved. Once daily dosing may not maintain the full effect for the entire dosing period, particularly at lower doses. In such patients, consider administration in divided doses. Dosing regimens that exceed 50 mg of hydrochlorothiazide per day are not recommended.
— FDA label: Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc., effective September 15, 2026. Read the full label on DailyMed →
Metoprolol tartrate and hydrochlorothiazide in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary Untreated hypertension during pregnancy can lead to adverse outcomes for the mother and the fetus (see Clinical Considerations). Available data from published observational studies have not demonstrated a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes with metoprolol use during pregnancy.
Read more of this section
However, there are inconsistent reports of intrauterine growth restriction, preterm birth, and perinatal mortality with maternal use of beta blockers, including metoprolol, during pregnancy (see Data). There have been rare reports of jaundice, thrombocytopenia, and electrolyte imbalances in infants exposed to thiazide medications during pregnancy. In animal reproduction studies, metoprolol has been shown to increase post-implantation loss and decrease neonatal survival in rats at oral dosages up to 24 times, on a mg/m 2 basis, the daily dose of 200 mg in a 60-kg patient. The combination of metoprolol tartrate/hydrochlorothiazide administered to rats from mid-late gestation through lactation also produced increased post-implantation loss and decreased neonatal survival (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Consideration Disease-Associated Maternal and/or Embryo/Fetal Risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal Adverse Reactions Metoprolol Metoprolol crosses the placenta. Neonates born to mothers who are receiving metoprolol during pregnancy, may be at risk for hypotension, hypoglycemia, bradycardia, and respiratory depression. Observe neonates for symptoms of hypotension, bradycardia, hypoglycemia and respiratory depression and manage accordingly. Data Human Data Data from published observational studies did not demonstrate an association of major congenital malformations and use of either metoprolol or hydrochlorothiazide in pregnancy. The published literature has reported inconsistent findings of intrauterine growth retardation, preterm birth and perinatal mortality with maternal use of metoprolol during pregnancy; however, these studies have methodological limitations hindering interpretation. Methodological limitations include retrospective design, concomitant use of other medications, and other unadjusted confounders that may account for the study findings including the underlying disease in the mother. These observational studies cannot definitely establish or exclude any drug-associated risk during pregnancy.
— FDA label: Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc., effective September 15, 2026. This is part of the section. Read the full label on DailyMed →
When Metoprolol tartrate and hydrochlorothiazide should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Metoprolol tartrate and hydrochlorothiazide tablets are contraindicated in patients with:
- Cardiogenic shock or decompensated heart failure.
- Sinus bradycardia, sick sinus syndrome, and greater than first-degree block unless a permanent pacemaker is in place.
- Anuria
- Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide-derived drugs.
- Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or other sulfonamide-derived drugs.
Read more of this section
(4)
- Cardiogenic shock or decompensated heart failure. (4)
- Sinus bradycardia, sick sinus syndrome, and greater than first-degree block unless a permanent pacemaker is in place. (4)
- Anuria. (4)
— FDA label: Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc., effective September 15, 2026. Read the full label on DailyMed →
Metoprolol tartrate and hydrochlorothiazide overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
Signs and Symptoms The most frequently observed signs expected with overdosage of a beta-adrenergic blocker are bradycardia and bradyarrhythmia, hypotension, heart failure, cardiac conduction disturbances and bronchospasm, atrioventricular block, hypoxia, impairment of consciousness/coma, cardiogenic shock, nausea and vomiting. With thiazide diuretics, acute intoxication is rare. The most prominent feature of overdose is acute loss of fluid, electrolytes and magnesium.
Read more of this section
Signs and symptoms of overdose may include hypotension, dizziness, muscle cramps, renal impairment or failure, and sedation/ impairment of consciousness. Altered laboratory findings can also occur (e.g., hypokalemia, hypomagnesemia, hyponatremia, hypochloremia, alkalosis, increased BUN). 10.2 Management Care should be provided at a facility that can provide appropriate supporting measures, monitoring and supervision as treatment is symptomatic and supportive and there is no specific antidote. Limited data suggest that neither metoprolol nor hydrochlorothiazide is dialyzable. If justified, gastric lavage and/or activated charcoal can be administered. Based on the expected pharmacologic actions and recommendations for other beta-adrenergic blockers and hydrochlorothiazide, the following measures should be considered when clinically warranted. Hemodialysis is unlikely to make a useful contribution to metoprolol elimination [see Clinical Pharmacology (12.3)]. Bradycardia and Conduction Disturbances Use atropine, adrenergic-stimulating drugs or pacemaker. Hypotension or Shock Treat underlying bradycardia. Consider intravenous expansion, vasopressors, injection of glucagon (if necessary, followed by an intravenous infusion of glucagon), or intravenous administration of adrenergic drugs such as dobutamine. Heart Failure Treat bradycardia if present and support hemodynamics with inotropes if necessary. Bronchospasm Can usually be reversed by bronchodilators.
— FDA label: Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc., effective September 15, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 14 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| hydrochlorothiazide 25 mg · metoprolol tartrate 100 mg tablet | Generic | $1.45 per tablet |
| hydrochlorothiazide 25 mg · metoprolol tartrate 50 mg tablet | Generic | $0.8815 per tablet |
| hydrochlorothiazide 50 mg · metoprolol tartrate 100 mg tablet | Generic | $1.36 per tablet |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Alembic Pharmaceuticals Limited3 products
- Alembic Pharmaceuticals Inc.3 products
- Mylan Pharmaceuticals Inc.3 products
- Sun Pharmaceutical Industries, Inc.3 products
- Ajanta Pharma USA Inc.2 products
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (4)
- ANDA076792Mylan · August 20, 2004
- ANDA090654Sun Pharm Inds · January 19, 2012
- ANDA202870Alembic · November 6, 2013
- ANDA215789Pharmazone · January 8, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 15, 2021 · Class II · Terminated · D-0412-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Metoprolol Tartrate and Hydrochlorothiazide Tablets, USP 50 mg/25 mg 100 Tablets Rx only NDC 62332-115-31 Manufactured for: Alembic Pharmaceuticals, Inc. 750 Route 202, Bridgewater, NJ 08807 USA — Cardinal Health Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 866479, 866482, 866491 |
|---|---|
| SPL set ID of the quoted label | b6cf0f43-8dc3-4535-b651-daf1f9e0336c |
| FDA labels (SPL) | 5 |
| FDA applications | 4 ANDA |
| Active ingredients (FDA) | HYDROCHLOROTHIAZIDE / METOPROLOL |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- Heart failureCondition named on the label: hospitals that treat it
- High blood pressureCondition named on the label: hospitals that treat it
- StrokeCondition named on the label: hospitals that treat it
- Alembic Pharmaceuticals LimitedMaker or distributor
- Alembic Pharmaceuticals Inc.Maker or distributor
- Mylan Pharmaceuticals Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Metoprolol Tartrate and Hydrochlorothiazide, Mylan Pharmaceuticals Inc., effective September 15, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →